SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice - in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner - Radek ...

SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice - in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner - Radek ...

User Photo
Cancer-News

3 months
45 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner

Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase 1 trial (NCT04234113)

- Poster shows new preclinical data detailing anti-tumor efficacy in tumor mouse models

- SO-C101 monotherapy significant reduced tumor growth in early and advanced treatment settings

- SO-C101 in combination with PD-1 inhibitors led to durable tumor response in a majority of mice, which was maintained after tumor re-challenge
Up Next Autoplay
>